Project Hail Mary author Andy Weir keeps on recommending this sci-fi book everywhere he goes, and it's not hard to understand ...

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...

OpenAI advances recursive AI; new startup pursues self-improving systems amid leaked experimental model names.

Generative artificial intelligence security startup Portal26 Inc. today announced the launch of a new module designed to rein ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

"output": "Here are your current orders, John:\n\n**Order #24601**\n- Product: Wireless Headphones\n- Quantity: 1\n- Price: $79.99\n- Status: Shipped\n\n**Order ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...